Full-year sales of JPY 47.9 billion, up 13% year on year
Market
• Tailwind: Achieve 80% usage rate for generic drugs by September 2020.
Volume is growing rapidly.
• Headwind: Major drug price reductions
New strategy for generic drug - preparing for upcoming drug price reduction
• Specialty generic drugs and essential generic drugs
• Use Medreich for low-cost production to expand essential generic drug business - lifestyle related diseases, gastrointestinal disease, and drugs need stable supply
Full-year sales of JPY 47.9 billion, up 13% year on year
Market• Tailwind: Achieve 80% usage rate for generic drugs by September 2020.
Volume is growing rapidly.
• Headwind: Major drug price reductions
New strategy for generic drug - preparing for upcoming drug price reduction• Specialty generic drugs and essential generic drugs
• Use Medreich for low-cost production to expand essential generic drug business - lifestyle related diseases, gastrointestinal disease, and drugs need stable supply
Essential generic drugs• Significant sales growth for injectable antibacterial drugs
Sulbacillin, Tazopipe drove sales.
• Built trust-based relationships with doctors in the infectious diseases domain
• Market providing tailwind
• Manufacturing Tazopipe in PT. Meiji Indonesia
Contributing to overall company revenues